Roots Analysis has done a detailed study on Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 230+ page report, which features 115+ figures and 110+ tables, please visit this link Key Market Insights Over 55 novel ophthalmic products […]
Recent technological advances in the field of ophthalmology and the availability of new biomaterials have substantially expanded the range of potential application areas of contact lenses and enabled the development of novel prosthetic products Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Contact Lenses and Visual Prostheses
With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter
Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes),
To order this detailed 670+ page report, please visit this link Key Inclusions A detailed review of the overall landscape of gene therapies and genome editing therapies, including information on various drug / therapy developer companies, phase of development (marketed, clinical, and preclinical / discovery stage) of pipeline candidates, key therapeutic areas (cardiovascular disorders, muscular
Gene Therapy Market (3rd Edition), 2019-2030 Read More »
Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes),
Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this link Key Market Insights In the past four years, more than 31,000
The gene therapy market is projected to grow at an annualized rate of 45%, till 2030 Read More »
With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”. The report features
To order this detailed 370+ page report, please visit this link Key Inclusions A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic
Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 Read More »
With various target combinations and novel mechanisms of action, bispecific antibodies are presently recognized as a potent class of targeted therapies, with the potential to be used as treatment options for a variety of disease indications. Several pipeline candidates have recently entered mid to late-stage (phase II and above) trials and are anticipated to enter
